About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our research group is focused on studying the pathophysiology of migraine and other primary headaches using preclinical, translational and clinical research.
Migraine will allow us to define the brain’s adaptive, sensory/cognitive functions, through genetics, epigenetics, neurophysiology, neuromolecular and neuroanatomical information with an interest in developing clinical therapeutic solutions, with the goal on having an impact on suffering and increasing the well-being.
PMID: 34601944 Journal: CEPHALALGIA Year: 2022 Reference: Cephalalgia. 2022 Mar;42(3):186-196. doi: 10.1177/03331024211040467. Epub 2021 Oct 4. Impact factor: Publication type: Paper in international publication Authors: Alpuente, Alicia; Asskour, Laila; Caronna, Edoardo; Gallardo, Victor J; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al. DOI: 10.1177/03331024211040467
PMID: 35383491 Journal: CEPHALALGIA Year: 2022 Reference: Cephalalgia. 2022 Apr;42(4-5):427-429. doi: 10.1177/03331024211070712. Impact factor: Publication type: Editorail in international publication Authors: Pozo-Rosich, Patricia et al. DOI: 10.1177/03331024211070712
PMID: 35372780 Journal: Future healthcare journal Year: 2022 Reference: Future Healthc J. 2022 Mar;9(1):34-40. doi: 10.7861/fhj.2021-0016. Impact factor: Publication type: Paper in international publication Authors: Carbonell-Cobo, Marta; Chaudry, Zafar; Emery, Lisa; Garcia-Cuyas, Francesc; Gates, Darren; Hennessey, Iain; Hueto-Madrid, Juan Antonio; Moz, Monica; Patt, Carol; Pozo-Rosich, Patricia et al. DOI: 10.7861/fhj.2021-0016
PMID: 34282471 Journal: JOURNAL OF NEUROLOGY Year: 2022 Reference: J Neurol. 2022 Mar;269(3):1456-1462. doi: 10.1007/s00415-021-10715-2. Epub 2021 Jul 20. Impact factor: Publication type: Paper in international publication Authors: Alpuente, Alicia; Caronna, Edoardo; Gallardo, Victor Jose; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al. DOI: 10.1007/s00415-021-10715-2
PMID: 33859216 Journal: Scientific Reports Year: 2021 Reference: Sci Rep. 2021 Apr 15;11(1):8286. doi: 10.1038/s41598-021-87352-2. Impact factor: Publication type: Paper in international publication Authors: Aguirre-Vazquez, M; Colomina, I; Correa-Fernandez, J; Garrido-Cumbrera, M; Irimia, P; Pozo-Rosich, P; Santos-Lasaosa, S et al. DOI: 10.1038/s41598-021-87352-2
PMID: 33291995 Journal: CEPHALALGIA Year: 2021 Reference: Cephalalgia. 2021 Apr;41(5):613-630. doi: 10.1177/0333102420974359. Epub 2020 Dec 8. Impact factor: Publication type: Review in international publication Authors: Coppola, Gianluca; Pascual, Julio; Pozo-Rosich, Patricia; Schwedt, Todd J et al. DOI: 10.1177/0333102420974359
PMID: 33773613 Journal: LANCET Year: 2021 Reference: Lancet. 2021 Apr 17;397(10283):1485-1495. doi: 10.1016/S0140-6736(20)32160-7. Epub 2021 Mar 25. Impact factor: Publication type: Review in international publication Authors: Ashina, Messoud; Ashina, Sait; Buse, Dawn C; Do, Thien Phu; Katsarava, Zaza; Krymchantowski, Abouch V; Lebedeva, Elena R; Lipton, Richard B; Ozge, Aynur; Pozo-Rosich, Patricia et al. DOI: 10.1016/S0140-6736(20)32160-7
PMID: 33773612 Journal: LANCET Year: 2021 Reference: Lancet. 2021 Apr 17;397(10283):1505-1518. doi: 10.1016/S0140-6736(20)32342-4. Epub 2021 Mar 25. Impact factor: Publication type: Review in international publication Authors: Ashina, Hakan; Ashina, Messoud; Buse, Dawn C; Do, Thien Phu; Dodick, David W; Halker Singh, Rashmi; Lee, Mi Ji; Mitsikostas, Dimos D; Peres, Mario F P; Pozo-Rosich, Patricia et al. DOI: 10.1016/S0140-6736(20)32342-4
PMID: 32664898 Journal: JOURNAL OF HEADACHE AND PAIN Year: 2020 Reference: J Headache Pain. 2020 Jul 14;21(1):90. doi: 10.1186/s10194-020-01135-0. Impact factor: 4.797 Publication type: Review in international publication Authors: Caronna, Edoardo, Benemei, Silvia, Labastida-Ramirez, Alejandro, Abramova, Ekaterina, Brunelli, Nicoletta, Diana, Paola, Gapeshin, Roman, Hofacker, Maxi Dana, Pias, Enrique Martinez, Maestrini, Ilaria et al. DOI: 10.1186/s10194-020-01135-0
PMID: 32657062 Journal: Journal of Clinical Neurology Year: 2020 Reference: J Clin Neurol. 2020 Jul;16(3):416-422. doi: 10.3988/jcn.2020.16.3.416. Impact factor: 2.439 Publication type: Paper in international publication Authors: Fonseca, Elena, Macaya, Alfons, Pozo-Rosich, Patricia, Gallardo, Victor Jose, Torres-Ferrus, Marta et al. DOI: 10.3988/jcn.2020.16.3.416
PMID: 32652924 Journal: JOURNAL OF HEADACHE AND PAIN Year: 2020 Reference: J Headache Pain. 2020 Jul 11;21(1):88. doi: 10.1186/s10194-020-01157-8. Impact factor: 4.797 Publication type: Paper in international publication Authors: Torres-Ferrus, Marta, Gallardo, Victor Jose, Alpuente, Alicia, Pozo-Rosich, Patricia et al. DOI: 10.1186/s10194-020-01157-8
PMID: 32614067 Journal: ACTA NEUROLOGICA SCANDINAVICA Year: 2020 Reference: Acta Neurol Scand. 2020 Dec;142(6):555-562. doi: 10.1111/ane.13302. Epub 2020 Jul 29. Impact factor: 2.684 Publication type: Paper in international publication Authors: Caronna, Edoardo, Sanchez Corral, Anna, Santafe, Manel, Sueiras, Maria, Guzman, Lorena, Quintana, Manuel, Toledo-Argany, Manuel, Santamarina, Estevo, Gracia Gozalo, Rosa Maria, Vilaseca, Andreu et al. DOI: 10.1111/ane.13302
Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.
